An interventional study of Tart cherry extract 60 mL and Tart cherry extract 120 mL in Gout, sponsored by Rutgers, The State University of New Jersey. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-09.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Other
The purpose of the study is to establish the pharmacokinetic parameters of cherry juice concentrate and identify its potential to alter inflammatory markers in gout patients.
232 studies on the registry are indexed under Gout; 45 are open to participants now.
This study's enrollment of 10 is below the median of 121 across 202 interventional studies indexed under Gout.
Browse Gout studies →Rutgers, The State University of New Jersey is the lead sponsor of 496 studies on the registry; 130 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 30 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
Dietary Supplement: Tart cherry extract 60 mL · Dietary Supplement: Tart cherry extract 120 mL
Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
Dietary Supplement: Tart cherry extract 60 mL · Dietary Supplement: Tart cherry extract 120 mL
Subjects will receive a single 60 mL oral dose of tart cherry extract.
Subjects will receive a single 120 mL oral dose of tart cherry extract.
Highly sensitive C-reactive protein (hs-CRP)
Reduction in hs-CRP
Time frame: Maximal change in hs-CRP from baseline through study completion (during the 12 hours after a dose)
Area under the curve (AUC)
The area under the plasma anthocyanin concentration-time curve
Time frame: Through study completion (during the 12 hours after a dose)
Change in inflammatory marker expression
Fold change in mRNA expression of Nrf2
Time frame: Through study completion (during the 12 hours after a dose)
Peak plasma concentration (Cmax)
Peak plasma concentration of anthocyanins
Time frame: Through study completion (during the 12 hours after a dose)
Time to peak plasma concentration (Tmax)
Time to achieve peak plasma anthocyanin concentration
Time frame: Through study completion (during the 12 hours after a dose)
Half-life (t1/2)
Plasma anthocyanin half-life
Time frame: Through study completion (during the 12 hours after a dose)
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey